- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Caplin Steriles Gets USFDA OAI Classification After 10 Observations at Tamil Nadu Facility

Chennai: Caplin Point Laboratories Limited has announced that its subsidiary, Caplin Steriles Limited, has received an Official Action Indicated (OAI) classification from the United States Food and Drug Administration (USFDA) following an inspection of its injectable and ophthalmic manufacturing facility at Gummidipoondi, Tamil Nadu.
In a regulatory disclosure, the company stated that the US FDA had conducted an unannounced inspection of the facility between August 13 and August 21, 2026. The inspection concluded with 10 observations, which the company described as procedural in nature.
Following the inspection, the US FDA determined the facility’s inspection classification as Official Action Indicated (OAI). The company stated that it received the communication regarding the classification on November 16, 2026.
Despite the regulatory development, Caplin Point Laboratories stated that it does not expect any material impact on its financials or operations as of the date of the disclosure. The company also confirmed that the facility continues to manufacture and supply products.
The company reiterated its commitment to maintaining high standards of quality, current Good Manufacturing Practices (cGMP) and regulatory compliance. It further stated that it would work closely with the US FDA to address the observations and demonstrate the effectiveness and sustainability of the corrective and preventive actions.
Caplin Point Laboratories also assured that it would keep the stock exchanges informed of any further developments related to the matter.
Caplin Point Laboratories Limited is a pharmaceutical company headquartered in Chennai, Tamil Nadu, engaged in pharmaceutical manufacturing and marketing. Its subsidiary, Caplin Steriles Limited, operates in the injectable and ophthalmic pharmaceutical segments, with its manufacturing facility at Gummidipoondi.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

